U.S. Markets closed

ChemoCentryx, Inc. (CCXI)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
55.95-1.33 (-2.32%)
At close: 4:00PM EST

55.95 0.00 (0.00%)
After hours: 4:03PM EST

Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close57.28
Bid55.80 x 800
Ask55.88 x 1200
Day's Range55.72 - 58.01
52 Week Range26.74 - 65.43
Avg. Volume597,400
Market Cap3.872B
Beta (5Y Monthly)1.76
PE Ratio (TTM)N/A
EPS (TTM)-0.65
Earnings DateNov 09, 2020
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est76.63
  • ChemoCentryx to Present at Two Upcoming Investor Conferences

    ChemoCentryx to Present at Two Upcoming Investor Conferences

    MOUNTAIN VIEW, Calif., Nov. 19, 2020 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq: CCXI), today announced that Thomas J. Schall, Ph.D., President and Chief Executive Officer, will present at two upcoming investor conferences: Piper Sandler 32nd Annual Virtual Healthcare Conference On-demand presentation available beginning Monday, November 23 at 10:00 a.m. Eastern TimeEvercore ISI 3rd Annual HealthCONx Conference Thursday, December 3, 2020 at 1:25 p.m. Eastern TimeA live audio webcast of the Evercore presentation and the on-demand Piper Sandler presentation can be accessed through the Investors section of the Company's website at www.ChemoCentryx.com. Both webcasts will be available on the Company's website for two weeks following the respective presentation dates.About ChemoCentryxChemoCentryx is a biopharmaceutical company developing new medications for inflammatory and autoimmune diseases and cancer. ChemoCentryx targets the chemokine and chemoattractant systems to discover, develop and commercialize orally administered therapies. ChemoCentryx’s lead drug candidate, avacopan (CCX168), successfully completed a pivotal Phase III trial in ANCA-associated vasculitis and a New Drug Application is under review by the U.S. Food and Drug Administration, along with a Marketing Authorization Application by the European Medicines Agency. Avacopan is also in late stage clinical development for the treatment of Hidradenitis Suppurativa and C3 glomerulopathy (C3G).ChemoCentryx also has early stage drug candidates that target chemoattractant receptors in other inflammatory and autoimmune diseases and in cancer.Contacts:Susan M. Kanaya Executive Vice President, Chief Financial and Administrative Officer investor@chemocentryx.comMedia: Stephanie Tomei 408.234.1279 media@chemocentryx.comInvestors: Lee Roth, Burns McClellan 212.213.0006 lroth@burnsmc.com

  • ChemoCentryx (CCXI) Reports Wider-Than-Expected Q3 Loss

    ChemoCentryx (CCXI) Reports Wider-Than-Expected Q3 Loss

    ChemoCentryx (CCXI) reports a wider-than-expected Q3 loss and misses sales estimates in the third quarter of 2020.

  • ChemoCentryx Inc (CCXI) Q3 2020 Earnings Call Transcript
    Motley Fool

    ChemoCentryx Inc (CCXI) Q3 2020 Earnings Call Transcript

    CCXI earnings call for the period ending September 30, 2020.